Business
Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors
Mr. Borkowski joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical and healthcare industry, including 7
About this update from Immix Biopharma, Inc.
[{"type":"text","content":" Mr. Borkowski joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical and healthcare industry, including 7 years as Chief Financial Officer of Mylan N.V. Mr. Borkowski is also the former Chief Financial Officer of CareFusion, which was ultimately acquired by Becton Dickinson for $12.2 billion LOS ANGELES, June 22, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that effective today, Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, has been appointed to the Company’s Board of Directors. Mr. Borkowski brings significant leadership in capital markets, finance, accounting, strategy, and mergers & acquisitions to Nexcella. After joining Mylan in 2002, Mr. Borkowski held positions of increasing responsibility including Chief Financial Officer and Executive Vice President from 2002 until 2009. In addition to his experience at Mylan, Mr. Borkowski was the former Chief Financial Officer of CareFusion, where he led the IPO. CareFusion was ultimately acquired by Becton Dickinson for $12.2 billion. “We are thrilled to have Mr. Borkowski join the Nexcella Board of Directors. He is a proven finance and capital markets leader of pharmaceutical organizations including Mylan and CareFusion, successfully navigating complex situations throughout his distinguished career, including Mylan N.V.’s interaction with Carl Icahn and other activist investors,” said Ilya Rachman, MD, Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “Mr. Borkowski’s deep capital markets and finance experience will be invaluable to our team, especially as we advance our NXC-201 CAR-T program into planned US clinical trials. We look forward to benefiting from his valuable guidance.” “I am delighted to join the Nexcella team and contribute my knowledge and expertise to developing therapies that benefit patients globally,” said Mr. Borkowski. “I look forward to working with the Nexcella team on their pioneering cell therapy programs.” In addition to his service at Mylan and CareFusion, Mr. Borkowski has served as a senior executive of a number of public and private biopharmaceutical, medical device, and healthcare companies in his career spanning over three deca...